查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751283

Perjeta 市場規模、佔有率、趨勢分析報告：按產品、適應症、分銷管道、地區、細分市場預測，2025 年至 2030 年

Perjeta Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibody, Generic Drug), By Indication (Early Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Perjeta 市場成長與趨勢：

根據Grand View Research, Inc.的最新報告，預計到2030年全球帕妥珠單抗市場規模將達到59.3億美元，2025年至2030年期間的複合年成長率為5.5%。

羅氏公司研發的單株抗體藥物帕捷特（Perjeta，Pertuzumab）在 HER2 陽性乳癌治療領域持續展現強勁勢頭，尤其在乳癌和轉移性乳癌治療中。作為聯合治療的一部分，帕捷特已證明在新輔助治療和轉移性治療方法中均能改善療效，鞏固了其在乳癌綜合治療中的地位。該藥物針對 HER2 受體以抑制癌細胞增殖的作用機制，使其成為現代腫瘤治療方案的基石。

帕妥珠單抗通常與曲妥珠單抗和化療合併使用，其在降低早期乳癌復發風險和延長轉移性乳癌無惡化生存期期方面的療效已得到可靠臨床數據的支持。乳癌發生率持續上升，加之人們對乳癌的認知不斷提高以及對早期診斷的重視，推動了對帕妥珠單抗等有效生物製藥的需求不斷成長。

醫院藥房仍然是帕妥珠單抗（Perjeta）分銷的核心，尤其是在治療早期，需要醫生監督和輸液基礎設施。隨著病人歷程治療過程的進展，專科藥房正在擴大其作用，為癌症患者提供客製化服務，包括輸液協調、個人化護理管理和依從性支援。這些藥房正在幫助接受複雜生物製藥治療的患者獲得持續的照護。

目前，帕妥珠單抗（Perjeta）是一種品牌藥，但未來學名藥和生物相似藥的推出可能會顯著改變市場格局。更具成本效益的替代品的出現將提高藥物的可近性，並減輕長期癌症治療的經濟負擔。這將產生重大影響，尤其是在新興市場以及面臨平衡創新與可負擔性壓力的醫療保健體系中。

與其他生物製藥一樣，供應鏈效率和低溫運輸物流對於維持藥品品質和供應仍然至關重要。專科藥局和線上藥局日益成長的作用，加上數位醫療和病患管理平台的進步，為克服這些挑戰並改善整體病患體驗提供了機會。

「對帕妥珠單抗（Perjeta）等先進療法的需求反映了腫瘤學領域向精準醫療的廣泛轉變。乳癌是全球最常見的癌症之一，對有針對性、有效的治療方案的需求從未如此強烈。像羅氏製​​藥這樣的公司持續創新，以及我們醫院和藥房網路的戰略夥伴關係關係，將是這一需求並改善全球患者治療的關鍵。

Perjeta 市場報告亮點

  • 從產品來看，單株抗體領域預計將在2024年佔據市場主導地位，鞏固其作為乳癌治療首選方案的地位。帕妥珠單抗是一種標靶單株抗體藥物，已證明對HER2陽性乳癌具有高度特異性和有效性，使其成為該領域的主要藥物類別。
  • 根據適應症，轉移性乳癌在 2024 年佔據了 Perjeta 市場的主導地位。該適應症正在推動對 Perjeta 的需求，因為它已被證明可以延長轉移性 HER2 陽性乳癌的無惡化生存期和整體存活期。
  • 從分銷管道來看，醫院藥房在 2024 年成為主要分銷管道。由於需要靜脈注射和密切的醫療監督，醫院藥局是 Perjeta 的主要分銷管道。
  • 北美憑藉其發達的醫療基礎設施、對帕妥珠單抗的高度認知以及先進的治療方案，推動著帕妥珠單抗市場的發展。該地區對研發和創新的重視也進一步推動了市場的成長。
  • 參與 Perjeta 市場的公司包括 F. Hoffmann-La Roche Ltd、Ambrx Biopharma、Charisma Therapeutics 和 Byondis。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章 Perjeta 市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 Perjeta 市場：產品業務分析

  • 2024年及2030年的產品市場佔有率
  • 產品細分儀表板
  • 市場規模、預測與趨勢分析（按產品，2018-2030 年）
  • 單株抗體
  • 學名藥

第5章 PERJETA 市場指標業務分析

  • 2024年及2030年指示市場佔有率
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（2018-2030 年）
  • 早期乳癌
  • 轉移性乳癌

第6章 Perjeta 市場：通路業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 專業藥房
  • 其他藥局

第7章 Perjeta 市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/列表
    • F. Hoffmann-La Roche Ltd
    • Ambrx Biopharma
    • Carisma Therapeutics
    • Byondis
Product Code: GVR-4-68040-590-2

Perjeta Market Growth & Trends:

The global perjeta market is anticipated to reach USD 5.93 billion by 2030 and is projected to grow at a CAGR of 5.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market for Perjeta (pertuzumab), a monoclonal antibody developed by F. Hoffmann-La Roche Ltd, continues to show strong momentum in the treatment of HER2-positive breast cancer, particularly in early-stage and metastatic settings. As part of combination therapies, Perjeta has demonstrated improved outcomes in both neoadjuvant and metastatic treatment regimens, solidifying its role in comprehensive breast cancer care. The drug's mechanism of action-targeting the HER2 receptor to inhibit cancer cell growth-has made it a cornerstone in modern oncology protocols.

Perjeta is commonly used in conjunction with trastuzumab and chemotherapy, and its efficacy in reducing the risk of disease recurrence in early breast cancer, as well as extending progression-free survival in metastatic cases, has been backed by robust clinical data. The continued rise in breast cancer incidence, along with growing awareness and early diagnosis initiatives, is driving increased demand for effective biologic therapies such as Perjeta.

Hospital pharmacies remain central to Perjeta's distribution, particularly during the initial phases of treatment, where medical supervision and infusion infrastructure are necessary. As patients progress through their treatment journey, specialty pharmacies play a growing role by offering services tailored to oncology patients, including infusion coordination, personalized care management, and adherence support. These pharmacies help ensure that patients undergoing complex biologic therapies maintain consistent access to treatment.

Although Perjeta is currently a branded therapy, the future introduction of a generic or biosimilar version could significantly reshape the market. The availability of more cost-effective alternatives would enhance accessibility and relieve some of the financial burden associated with long-term cancer treatment. This would be particularly impactful in emerging markets and health systems under pressure to balance innovation with affordability.

As with other biologic therapies, supply chain efficiency and cold chain logistics remain critical to maintaining drug quality and availability. The growing role of specialty and online pharmacies, combined with advancements in digital health and patient management platforms, offers opportunities to overcome these challenges and improve the overall patient experience.

The demand for advanced therapies like Perjeta reflects a broader shift toward precision medicine in oncology. With breast cancer remaining one of the most prevalent cancers worldwide, the need for targeted, effective treatment options is stronger than ever. Continued innovation by companies like F. Hoffmann-La Roche Ltd, along with strategic partnerships across hospital and pharmacy networks, will be key in meeting this demand and improving outcomes for breast cancer patients globally.

Perjeta Market Report Highlights:

  • Based on product, the monoclonal antibody segment dominated the market in 2024, solidifying its position as the preferred treatment option for breast cancer management. Perjeta is a targeted monoclonal antibody therapy, offering high specificity and effectiveness against HER2-positive breast cancer, making it the dominant drug class in this market segment.
  • Based on indication, metastatic breast cancer segment dominated the Perjeta market in 2024. Its proven ability to extend progression-free and overall survival in metastatic HER2-positive breast cancer makes this indication the primary driver of Perjeta's demand.
  • Based on distribution channel, hsopital pharmacies emerged as the dominant distribution channel in 2024. Due to the need for intravenous administration and close medical supervision, hospital pharmacies are the main distribution channel for Perjeta.
  • North America led the Perjeta market, attributed to factors such as a well-established healthcare infrastructure, high awareness of about disease, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.
  • Companies operating in the Perjeta market include F. Hoffmann-La Roche Ltd, Ambrx Biopharma, Carisma Therapeutics, and Byondis.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Perjeta Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
      • 3.3.3.1. Phase 1
      • 3.3.3.2. Phase 2
      • 3.3.3.3. Phase 3
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Perjeta Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibody
    • 4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
  • 4.5. Generic Drug
    • 4.5.1. Generic Drug Market, 2018 - 2030 (USD Million)

Chapter 5. Perjeta Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Early Breast Cancer
    • 5.4.1. Early Breast Cancer Market, 2018 - 2030 (USD Million)
  • 5.5. Metastatic Breast Cancer
    • 5.5.1. Metastatic Breast Cancer Market, 2018 - 2030 (USD Million)

Chapter 6. Perjeta Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Other Pharmacies
    • 6.6.1. Other Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Perjeta Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. North America Perjeta Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Perjeta Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. F. Hoffmann-La Roche Ltd
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Ambrx Biopharma
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Carisma Therapeutics
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Byondis
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Perjeta market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 6 Global Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 9 North America Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 10 North America Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 12 U.S. Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 13 U.S. Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 15 Canada Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Canada Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 18 Mexico Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Mexico Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 22 Europe Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 23 Europe Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 25 UK Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 26 UK Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 28 Germany Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Germany Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 31 France Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 32 France Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 34 Italy Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Italy Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 37 Spain Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Spain Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 40 Norway Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 41 Norway Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 43 Denmark Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Denmark Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 46 Sweden Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Sweden Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Japan Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 53 Japan Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Japan Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 China Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 56 China Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 57 China Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 59 India Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 60 India Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Australia Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 62 Australia Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 63 Australia Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 65 South Korea Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 66 South Korea Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 68 Thailand Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 69 Thailand Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 72 Latin America Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 73 Latin America Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 75 Brazil Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 76 Brazil Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 78 Argentina Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 79 Argentina Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 85 South Africa Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 86 South Africa Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 91 UAE Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 92 UAE Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Perjeta market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Perjeta market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Perjeta market dynamics
  • Fig. 12 Perjeta market: Porter's five forces analysis
  • Fig. 13 Perjeta market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Monoclonal antibody market, 2018 - 2030 (USD Million)
  • Fig. 16 Generic drug market, 2018 - 2030 (USD Million)
  • Fig. 17 Indication market, 2018 - 2030 (USD Million)
  • Fig. 18 Early breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 19 Metastatic breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 20 Distribution channel market, 2018 - 2030 (USD Million)
  • Fig. 21 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 22 Specialty pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 23 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 24 Perjeta market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 68 MEA Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis, 2024
  • Fig. 79 Strategic framework